Nifty
:
14343.40
Sensex
:
47904.63
-491.45 (-3.31%)
-1686.69 (-3.40%)
Nifty
Sensex
:
:
14343.40
47904.63
-491.45 (-3.31%)
-1686.69 (-3.40%)

Cipla Ltd.

Pharmaceuticals & Drugs - Global

Rating :
53/99

BSE: 500087 | NSE: CIPLA

NSE BSE
883.05
09-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  840.90
  •  892.30
  •  836.65
  •  842.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  11189432
  •  97935.07
  •  892.30
  •  565.60

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 71,154.26
  • 31.80
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 72,966.78
  • 0.45%
  • 3.99

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.70%
  • 5.58%
  • 16.33%
  • FII
  • DII
  • Others
  • 22.09%
  • 17.57%
  • 1.73%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.48
  • 4.73
  • 4.17

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.54
  • 4.61
  • 4.83

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.12
  • 3.04
  • 4.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.19
  • 34.52
  • 31.45

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.57
  • 3.31
  • 3.12

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.76
  • 16.33
  • 14.47

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
5,168.69
4,371.00
18.25%
5,038.29
4,395.78
14.62%
4,346.16
3,989.02
8.95%
4,376.19
4,403.98
-0.63%
Expenses
3,937.81
3,612.67
9.00%
3,861.72
3,486.28
10.77%
3,297.42
3,084.38
6.91%
3,742.67
3,442.93
8.71%
EBITDA
1,230.88
758.33
62.31%
1,176.57
909.50
29.36%
1,048.74
904.64
15.93%
633.52
961.05
-34.08%
EBIDTM
23.81%
17.35%
23.35%
20.69%
24.13%
22.68%
14.01%
14.01%
Other Income
86.94
72.13
20.53%
53.47
100.52
-46.81%
65.45
78.37
-16.49%
93.18
95.36
-2.29%
Interest
47.92
46.17
3.79%
39.33
46.07
-14.63%
46.00
52.12
-11.74%
53.00
44.78
18.36%
Depreciation
248.43
277.89
-10.60%
265.06
282.96
-6.33%
268.98
268.00
0.37%
345.80
510.28
-32.23%
PBT
1,021.47
506.40
101.71%
925.65
680.99
35.93%
799.21
662.89
20.56%
327.90
501.35
-34.60%
Tax
268.96
152.82
76.00%
263.80
200.55
31.54%
227.78
192.24
18.49%
85.59
127.75
-33.00%
PAT
752.51
353.58
112.83%
661.85
480.44
37.76%
571.43
470.65
21.41%
242.31
373.60
-35.14%
PATM
14.56%
8.09%
13.14%
10.93%
13.15%
11.80%
7.11%
7.11%
EPS
9.28
4.35
113.33%
8.25
5.85
41.03%
7.17
5.93
20.91%
28.29
28.29
0.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
18,929.33
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
Net Sales Growth
10.31%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
 
Cost Of Goods Sold
10,173.57
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
Gross Profit
8,755.76
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
GP Margin
46.25%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
Total Expenditure
14,839.62
14,025.88
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
Power & Fuel Cost
-
327.43
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
% Of Sales
-
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
Employee Cost
-
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
% Of Sales
-
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
Manufacturing Exp.
-
1,372.03
1,284.94
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
% Of Sales
-
8.01%
7.85%
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
General & Admin Exp.
-
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
% Of Sales
-
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
Selling & Distn. Exp.
-
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
% Of Sales
-
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
Miscellaneous Exp.
-
766.82
855.40
968.98
645.54
83.99
497.67
441.10
355.12
194.07
386.67
% Of Sales
-
4.48%
5.23%
6.39%
4.48%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
EBITDA
4,089.71
3,106.11
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
EBITDA Margin
21.61%
18.13%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
Other Income
299.04
369.38
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
Interest
186.25
197.36
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
Depreciation
1,128.27
1,099.95
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
PBT
3,074.23
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
Tax
846.13
631.20
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
Tax Rate
27.52%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
PAT
2,228.10
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
PAT before Minority Interest
2,242.59
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
Minority Interest
14.49
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
PAT Margin
11.77%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
PAT Growth
32.76%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
 
EPS
27.67
19.80
19.19
17.55
12.59
17.04
14.98
17.40
19.27
14.18
12.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
Share Capital
161.25
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
Total Reserves
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
Non-Current Liabilities
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
Secured Loans
304.74
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
Unsecured Loans
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
Long Term Provisions
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
Current Liabilities
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
Trade Payables
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
Other Current Liabilities
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
Short Term Borrowings
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
Short Term Provisions
957.53
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
Total Liabilities
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
Net Block
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
Gross Block
15,009.61
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
Accumulated Depreciation
5,405.29
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
Non Current Assets
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
Capital Work in Progress
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
Non Current Investment
578.80
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
Long Term Loans & Adv.
677.08
455.57
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
Other Non Current Assets
77.61
166.82
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
Current Assets
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
Current Investments
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
Inventories
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
Sundry Debtors
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
Cash & Bank
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
Other Current Assets
1,416.84
415.53
480.20
418.17
1,223.17
858.67
630.63
468.31
622.17
726.59
Short Term Loans & Adv.
974.82
1,150.95
1,118.93
807.84
786.12
713.07
595.13
463.21
459.94
533.77
Net Current Assets
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
Total Assets
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
PBT
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
Adjustment
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
Changes in Working Capital
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
Cash after chg. in Working capital
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
Net Fixed Assets
-489.16
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
Net Investments
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
Others
2,032.35
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
Cash from Financing Activity
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
Net Cash Inflow / Outflow
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
Opening Cash & Equivalents
508.36
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
Closing Cash & Equivalent
742.38
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
194.85
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
ROA
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
ROE
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
ROCE
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
Fixed Asset Turnover
1.88
1.79
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
Receivable days
54.10
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
Inventory Days
56.12
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
Payable days
57.55
59.02
57.37
46.96
48.81
52.17
44.93
48.58
50.51
56.11
Cash Conversion Cycle
52.66
57.47
101.50
106.05
109.24
112.14
107.41
113.72
123.59
128.78
Total Debt/Equity
0.18
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
Interest Cover
12.04
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Cipla enters into agreement to become partner in ABCD Technologies LLP
    31st Mar 2021, 13:37 PM

    The target entity is a recently incorporated limited liability partnership

    Read More
  • Cipla’s affiliate enters into strategic partnership with SIGA Technologies
    23rd Mar 2021, 09:15 AM

    The partnership aims to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats

    Read More
  • Cipla pledges support to ‘Terra Carta’ for sustainable future
    19th Mar 2021, 09:39 AM

    Since its launch in January 2021, the initiative has received support from 223 private sector organisations and 21 professional associations

    Read More
  • Cipla voluntarily liquidates wholly-owned step-down subsidiary
    8th Mar 2021, 10:46 AM

    This liquidation was a part of internal reorganization and it will not affect the performance or revenue of the company

    Read More
  • Cipla's arm expands partnership with Alvotech
    2nd Mar 2021, 09:45 AM

    The partnership is for the marketing and distribution of four biosimilar medicines in Australia and New Zealand

    Read More
  • Cipla receives USFDA’s final approval for Sumatriptan Nasal Spray
    2nd Mar 2021, 09:30 AM

    Cipla’s Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline’s Imitrex Nasal Spray

    Read More
  • Cipla reports 2-fold jump in Q3 consolidated net profit
    1st Feb 2021, 11:27 AM

    Total income of the company increased by 18.29% at Rs 5255.63 crore for Q3FY21

    Read More
  • Cipla recalling over 5.8 lakh packets of gastric ulcer treatment drug in US
    11th Jan 2021, 09:58 AM

    The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.